In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
In this video filmed at Psych Congress 2024, Kristian Dambrino, DNP, PMHNP-BC, shares practical insights on tackling challenges that may arise when treating patients with tardive dyskinesia (TD).
In this video filmed at Psych Congress 2024, Kristian Dambrino, DNP, PMHNP-BC, shares practical insights on tackling challenges that may arise when treating patients with tardive dyskinesia (TD).
In this video, Psych Congress Steering Committee Member Jonathan Meyer, MD, explores TD treatment approaches that can optimize a patient’s overall well-being.
In this video, Psych Congress Steering Committee Member Jonathan Meyer, MD, explores TD treatment approaches that can optimize a patient’s overall well-being.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.